Drugs / Nicorandil
Trials 26
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 24 trials | ||||||
| Phase 2 | NCT05399576 | May 2022 → May 2023 | coronary artery disorder | The First Affiliated Hospital of Zhejiang Chinese Medical University | Unknown | No outcome recorded |
| Phase 2 | NCT04120766 | Dec 2021 → Sep 2026 overdue | cognitive impairment with or without cerebellar ataxia, dementia | Gregory Jicha, MD, PhD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04846621 | Jun 2020 → Jun 2021 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT02809456 | Jul 2016 → Jul 2019 | radiation pneumonitis | Taipei Medical University WanFang Hospital | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07730723 | Sep 2026 → Jul 2027 expected | rheumatoid arthritis | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06423729 | Jun → Dec 2024 | type 2 diabetes mellitus | Tanta University | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07800351 | Sep 2026 → Feb 2027 expected | atherosclerosis, rheumatoid arthritis | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04813471 | Jan → Mar 2021 | COVID-19 | Lebanese American University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04631536 | Jan 2021 → Mar 2022 | COVID-19 | Lebanese American University Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT02449070 | May 2015 → Oct 2018 | myocardial infarction | Pusan National University Hospital | Unknown | No outcome recorded |
| Phase 413 trials · 4 met primary | ||||||
| Phase 4 | NCT06787430 | Mar → Dec 2026 expected | ST-elevation myocardial infarction | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05427786 | Dec 2022 → May 2027 expected | coronary artery disorder | Korea University Anam Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04665648 | Jun 2021 → Dec 2024 | ST-elevation myocardial infarction | Fudan University | Completed | No outcome recorded |
| Phase 4 | NCT04826497 | Apr → Dec 2021 | coronary artery disorder | Xuzhou Central Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04310995 | Jun 2020 → Feb 2023 | coronary artery disorder | Ruijin Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05087797 | Apr 2019 → Jul 2020 | coronary artery disorder | Peking University Third Hospital | Completed | Met primary |
| Phase 4 | NCT03445728 | Feb 2018 → Jul 2020 | myocardial infarction | Chinese PLA General Hospital | Completed | Met primary |
| Phase 4 | NCT03252665 | Sep 2017 → Jun 2019 | ST-elevation myocardial infarction | RenJi Hospital | Unknown | Met primary |
| Phase 4 | NCT03010423 | Nov 2016 → Jul 2019 | nonobstructive coronary artery disease | Merck KGaA, Darmstadt, Germany | Terminated | No outcome recorded |
| Phase 4 | NCT02328521 | Dec 2014 → Jun 2016 | diabetes mellitus, intermediate coronary syndrome | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01396395 | Sep 2011 → May 2014 | coronary artery disorder | Merck KGaA, Darmstadt, Germany | Completed | Met primary |
| Phase 4 | NCT01185015 | Jan 2011 | — | Merck KGaA, Darmstadt, Germany | Withdrawn | No outcome recorded |
| Phase 4 | NCT01103336 | Mar 2010 → Jun 2011 | chronic renal failure syndrome | Yonsei University | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT03775902 | Dec 2018 → Jan 2020 | — | University of Copenhagen | Completed | No outcome recorded |
| — | NCT00424801 | Jan 2007 → Dec 2008 | coronary microvascular disorder, essential hypertension | University of Aarhus | Terminated | No outcome recorded |
| — | NCT00848562 | Jan 2002 → Dec 2006 | acute myocardial infarction, congestive heart failure | Toujinkai Hospital | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 1/2 | NCT07138508 Comparator | Mar 2024 → Feb 2025 | ST-elevation myocardial infarction | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT07516769 Comparator | Nov 2024 → Mar 2027 expected | rheumatoid arthritis | Tanta University | Recruiting | No outcome recorded |
| Phase 3 | NCT06430125 Comparator | Feb 2023 → Feb 2025 | type 2 diabetes mellitus | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT02435797 Comparator | Apr → Aug 2015 | coronary artery disorder | Xuzhou Central Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02254252 Comparator | Mar 2012 → Mar 2013 | nonobstructive coronary artery disease | Mashhad University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT01397994 Comparator | Sep 2011 → Jan 2012 | intermediate coronary syndrome | Ferozsons Laboratories Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT01475123 Comparator | Jun 2008 → Jun 2011 overdue | coronary artery disorder, end stage renal failure | Kumamoto University | Active not recruiting | No outcome recorded |
| — | NCT04646278 Background | Apr 2017 → Mar 2020 | coronary artery disorder | KangWon National University Hospital | Completed | No outcome recorded |
| — | NCT00212030 Comparator | Oct 2001 → Dec 2005 | acute myocardial infarction | National Cerebral and Cardiovascular Center, Japan | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 35 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nicorandil | “Nicorandil (potassium channel activator) is claimed to be as effective as Nifedipine (calcium channel blocker) for tocolysis in preterm labour” NCT04846621 ↗34“Nicorandil Nicorandil 10 mg PO BID for the first 7 days and then if no contraindications escalated to 20 mg PO BID for the remaining 7 days” NCT04813471 ↗ “The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.” NCT01396395 ↗ “Hyperemic simuli of coronary flow by adenosine or nicorandil injection” NCT04646278 ↗ |
| Known as | Ikorel | “20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)” NCT03775902 ↗ |
| Known as | NIC | “20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)” NCT03775902 ↗ |
| Known as | Nicorandil/ Nicoril | “Nicorandil/ Nicoril” NCT01397994 ↗ |
| Known as | Sigmart | “Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting” NCT01103336 ↗1“Sigmart (nicorandil)” NCT01185015 ↗ |
| Action | Activate | “an ATP-sensitive K+ (KATP) channel opener” NCT00212030 ↗ |
| Modality | Other / unclassified | “a hybrid of nitrate and adenosine triphosphate-sensitive potassium channel opener” NCT00848562 ↗ |
| Route | Intravenous | “receive either intravenous nicorandil or placebo” NCT00212030 ↗ |
| Target | ABCC9 | “Modulation of ABCC9 Pathways by Nicorandil” NCT04120766 ↗ |